(Q28069975)

English

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis

scientific article

In more languages

Statements

scholarly article

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

2 references

Europe PubMed Central

6 August 2020

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis (English)

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

5 references

24 March 2019

17 November 2019

20 November 2019

19 December 2019

6 August 2020

1 reference

17 November 2019

1 reference

20 November 2019

nerve tissue proteins

1 reference

19 December 2019

Natriuretic peptide, brain type

1 reference

6 August 2020

1 reference

based on heuristic

inferred from title

Angela Dispenzieri

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Giovanni Palladini

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

5

object named as

M A Gertz

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

G Merlini

1

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

I Lousada

2

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

M Grogan

6

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

M S Maurer

7

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

V Sanchorawala

8

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

A Wechalekar

9

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

R L Comenzo

11

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Yukio Ando

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

language of work or name

1 reference

publication date

15 July 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 October 2016

1 reference

6 August 2020

7 references

24 March 2019

17 November 2019

20 November 2019

19 December 2019

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

6 August 2020

30

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1979-1986

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

10

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

copyright license

Creative Commons Attribution 4.0 International

5 references

Europe PubMed Central

24 March 2019

Europe PubMed Central

17 November 2019

Europe PubMed Central

20 November 2019

Europe PubMed Central

19 December 2019

Europe PubMed Central

6 August 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

20 March 2017

Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

20 March 2017

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Novel strategies for the diagnosis and treatment of cardiac amyloidosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Cardiovascular magnetic resonance for amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

State of the art of immunoassay methods for B-type natriuretic peptides: An update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

T1 mapping and survival in systemic light-chain amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Pathophysiology and treatment of cardiac amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Immunoglobulin light chain amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Cardiac amyloidosis: updates in diagnosis and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Systemic amyloidosis in England: an epidemiological study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Biomarkers and diagnostics in heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

What do I need to know about immunoglobulin light chain (AL) amyloidosis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Emerging biomarkers in heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Amyloidosis: pathogenesis and new therapeutic options.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Clinical aspects of systemic amyloid diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

2 June 2018

How to image cardiac amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

2 June 2018

Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

2 June 2018

Systemic light chain amyloidosis: an update for treating physicians

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Light chain amyloidosis: the heart of the problem

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Comparison of brain natriuretic peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

B-type natriuretic peptide -- a window to the heart.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Mechanical strain increases expression of the brain natriuretic peptide gene in rat cardiac myocytes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Distinct regulation of B-type natriuretic peptide transcription by p38 MAPK isoforms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts

1 reference

https://pubmed.ncbi.nlm.nih.gov/27416985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiac amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27416985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/27416985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27416985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines on the management of AL amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27416985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2016.191

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Dimensions Publication ID

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Springer Nature article ID

10.1038/leu.2016.191

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28069975&oldid=1962483180"